Purpose: To explore the use of an ex vivo, in situ porcine cornea as a model for dry eye (exposure keratitis).
Methods: Twenty-seven porcine eyes were obtained from freshly killed animals at the local abattoir. The viability of 9 corneas (control-baseline group) was assessed within 5 minutes after enucleation on site. A further 18 eyes were transported to the laboratory, where they were exposed to ambient conditions for 4 hours (experimental group A, 6 eyes), for 6 hours (experimental group B, 6 eyes), and for 4 hours with wetting with Dulbecco Phosphate-Buffered Saline every 5 minutes (exposure control group, 6 eyes). All corneas were assessed by trypan blue exclusion for cell viability.
Results: The number of dead cells in the central region was significantly greater than those in the peripheral region (P < 0.05) in all groups. The number of dead cells in both corneal areas increased significantly (P < 0.05) in the experimental groups with time of exposure, but there was no significant increase in the exposure control group.
Conclusion: Preliminary data on the number of dead cells in porcine corneal epithelium after enucleation and the effect of exposure were obtained. It was found that after exposure to air, the corneal cells were maintained well by regular wetting, but there was progressively greater cell damage with exposure without wetting. These baseline data will be useful for the further development of the porcine dry eye model to investigate exposure keratitis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.ico.0000127475.29551.56 | DOI Listing |
Expert Opin Drug Saf
January 2025
Department of Pharmacy, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, Shandong, China.
Background: Adverse events (AE) in dupilumab induced ocular surface diseases (DIOSD) have raised concerns regarding its safety. The objective of this study was to evaluate DIOSD by employing database analysis and clinical case review, along with mechanism analysis.
Research Design And Methods: Database AE data were extracted from FAERS from 2017 Quarter 1 (Q1) to 2023 Q1.
Ocul Surf
December 2024
Centre for Ocular Research and Education (CORE), School of Optometry and Vision Science, University of Waterloo, Canada; Optometry and Vision Science Research Group, College of Health and Life Sciences, Aston University, Birmingham, United Kingdom; Department of Ophthalmology, Aotearoa New Zealand National Eye Centre, The University of Auckland, New Zealand.
Aims: To understand current clinical management of dry eye disease (DED), based on its perceived severity and subtype by practitioners across the world.
Methods: The content of the anonymous survey was chosen to reflect the DED management strategies reported by the Tear Film and Ocular Surface Society (TFOS) 2 Dry Eye Workshop (DEWS II). Questions were designed to ascertain practitioner treatment choice, depending on the subtype and severity of DED.
Sci Rep
December 2024
Eye Center, Renmin Hospital of Wuhan University, No. 238 Jiefang Road, Wuhan, 430060, Hubei, China.
Dry Eye Disease (DED) is a common condition worldwide, with smoking being recognized as a possible aggravating factor. Although observational studies have indicated a potential correlation, the findings have been inconclusive. In the study, Mendelian randomization (MR) analysis is used to investigate this potential causal relationship.
View Article and Find Full Text PDFFront Med (Lausanne)
December 2024
Department of Ophthalmology, Zhangye People's Hospital Affiliated to Hexi University, Zhangye, China.
Objective: Blood component therapy has shown promising potential as an emerging treatment for dry eye disease; however, it remains unclear which specific blood component is the most effective. This study aims to compare the efficacy of different blood components in the treatment of dry eye disease through a network meta-analysis, with the goal of providing the latest and most reliable evidence for clinical practice.
Methods: We conducted a systematic search of the PubMed, Web of Science, Cochrane, Embase, and Scopus databases, with the search concluding on June 1, 2024.
Ocul Surf
December 2024
AZURA Ophthalmics, Tel-Aviv, Israel.
Background: Contact lens discomfort (CLD) is a common problem for CL wearers, and patients with CLD often have changes in meibomian gland function and structure. In a Phase 2 trial AZR-MD-001 0.5% (AZR) ophthalmic ointment improved meibomian gland dysfunction (MGD) in non-lens wearers.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!